Content analysis of IQOS direct mail and email marketing in the US
- PMID: 38375169
- PMCID: PMC10874834
- DOI: 10.1016/j.pmedr.2024.102634
Content analysis of IQOS direct mail and email marketing in the US
Abstract
Objective: Novel nicotine and tobacco products, including heated tobacco products (HTPs) like IQOS, are growing in global popularity. IQOS was the first HTP authorized for sale by the US Food and Drug Administration, entering the US market in 2019 and being removed in 2021 due to patent-related legal challenges, with the possibility of returning in 2024. Direct marketing is one method tobacco companies use to reach consumers of these products. The purpose of this study was to investigate the content of US IQOS direct mail and email marketing.
Methods: Direct marketing items were collected between September 2019 and July 2021 by seven team members in the first US IQOS test market, Atlanta, Georgia.
Results: Overall, 101 marketing items were collected, 59 of which were unique. Among the unique items that showed images of persons ("models"), 70 % showed models appearing to be from racial/ethnic minoritized groups, 86.8 % showed at least one female-presenting model, and 37.5 % showed models appearing to be young adults (18-29 years). Items often had an embedded link/URL (91.5 %) and mentioned topics such as online services (54.2 %; for example, online ordering and tutorials), user experience (49.2 %), social media (44.1 %), and purchasing locations (37.3 %). When examined for their main purpose, items focused on subjects such as store experience (37.7 %), product introduction (18.6 %), and product use (15.3 %).
Conclusions: Our study highlights the importance of better understanding how novel tobacco products are marketed, which can inform policymakers' regulatory efforts and product authorization decisions.
Keywords: Content analysis; Direct marketing; Email/mail marketing; Heated tobacco products; IQOS; Marketing; Tobacco.
Published by Elsevier Inc.
Conflict of interest statement
David L. Ashley has received funds for work done for the World Health Organization Tobacco Free Initiative, as a Special Government Employee of the U.S. Food and Drug Administration, as a consultant for Pfizer, as an employee of Cherokee National Operational Systems and as an independent contractor for McKing Consulting. Dr. Pechacek has served as an expert in litigation involving e-cigarettes. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Similar articles
-
Discussion of Heated Tobacco Products on Twitter Following IQOS's Modified-Risk Tobacco Product Authorization and US Import Ban: Content Analysis.J Med Internet Res. 2024 Oct 24;26:e53938. doi: 10.2196/53938. J Med Internet Res. 2024. PMID: 39446431 Free PMC article.
-
IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.Int J Environ Res Public Health. 2021 Oct 8;18(19):10551. doi: 10.3390/ijerph181910551. Int J Environ Res Public Health. 2021. PMID: 34639851 Free PMC article.
-
Brief report on IQOS point-of-sale marketing, promotion and pricing in IQOS retail partner stores in Atlanta, Georgia, USA.Tob Control. 2023 Aug;32(e2):e260-e264. doi: 10.1136/tc-2022-057285. Epub 2022 Aug 2. Tob Control. 2023. PMID: 35918133 Free PMC article.
-
FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.Tob Control. 2022 Aug;31(e1):e83-e87. doi: 10.1136/tobaccocontrol-2020-056316. Epub 2021 Apr 2. Tob Control. 2022. PMID: 33811155 Free PMC article.
-
Characterizing Heated Tobacco Products Marketing on Instagram: Observational Study.JMIR Form Res. 2023 Mar 15;7:e43334. doi: 10.2196/43334. JMIR Form Res. 2023. PMID: 36920463 Free PMC article.
References
-
- Berg C.J., Romm K.F., Bar-Zeev Y., Abroms L.C., Klinkhammer K., Wysota C.N., Khayat A., Broniatowski D.A., Levine H. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation. Tob Control. 2023;32(4):418–427. doi: 10.1093/ntr/ntad096. - DOI - PMC - PubMed
-
- Choi K., Chen J.C., Tan A.S., Soneji S., Moran M.B. Receipt of tobacco direct mail/email discount coupons and trajectories of cigarette smoking behaviours in a nationally representative longitudinal cohort of US adults. Tob Control. 2019;28(3):282–1228. doi: 10.1136/tobaccocontrol-2018-054363. - DOI - PMC - PubMed
-
- Churchill V., Weaver S.R., Spears C.A., Huang J., Massey Z.B., Fairman R.T., Pechacek T.F., Ashley D.L., Popova L. IQOS debut in the USA: Philip Morris International’s heated tobacco device introduced in Atlanta, Georgia. Tob Control. 2020;29(e1):e152–e154. doi: 10.1136/tobaccocontrol-2019-055488. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources